Aydah AlAwadhi, Consultant Medical Oncologist and Division Chair of Hematology and Oncology Department at Sheikh Shakbout Medical City, Abu Dhabi, shared a post on LinkedIn:
“A major unmet need in advanced non-small cell lung cancer (NSCLC):
An excellent read highlighting patients with advanced NSCLC without actionable mutations, who have progressed beyond platinum chemotherapy and immunotherapy – a group with very limited treatment options and poor outcomes.
While antiangiogenic + ICI combinations have shown mixed results, bispecific antibodies (e.g., ivonescimab) are emerging as promising options. AI-driven tools may further refine treatment selection, while CAR-T remains investigational.
Future progress will depend on predictive biomarkers and a better understanding of ICI resistance to guide next-generation therapies.
Important read for the thoracic oncology community.”
Title: What is on the Horizon Beyond Platinum and Immunotherapy for Patients With Advanced Non–Small Cell Lung Cancer Without Actionable Genomic Aberrations?
Authors: Amanda Ribeiro Rangel, Gabriel Cavalcante Lima Chagas, Rafael Cavalcante Lima Chagas, Badi El Osta
More posts featuring Aydah AlAwadhi on OncoDaily.